Oruka Therapeutics, Inc.

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference